Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, By Distribution Channel, and By Region

Description

Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market is estimated to be valued at USD 154.3 Mn in 2025 and is expected to reach USD 1,610.3 Mn by 2032, growing at a compound annual growth rate (CAGR) of 39.8% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 154.3 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	39.80%	2032 Value Projection:	USD 1,610.3 Mn

Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a rare condition that affects the liver. People with this condition generally develop signs and symptoms during infancy, which may include severe itching, jaundice, portal hypertension (high blood pressure in the vein that provides blood to the liver) and hepatosplenomegaly (enlarged liver and spleen). PFIC2 generally progresses to liver failure in the first few years of life. Affected people also have an increased risk of developing hepatocellular carcinoma (a form of liver cancer). PFIC2 is caused by change (mutations) in the ABCB11 gene and is inherited in an autosomal recessive manner. Treatment options include ursodeoxycholic acid therapy to prevent liver damage, surgery, and/or liver transplantation. There are three known types of PFIC: PFIC1, PFIC2, and PFIC3.

Market Dynamics

Increasing awareness about progressive familial intrahepatic cholestasis type 2 disease is expected to provide more opportunities for players in the progressive familial intrahepatic cholestasis type 2 treatment market in the near future. For instance, on October 3, 2019, Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced its support for PFIC Awareness Day and reaffirmed its commitment to patients and families living with progressive familial intrahepatic cholestasis (PFIC).

However, higher economic growth in low- and middle-income countries has not closed the gap in health spending, and global inequity in health spending has remained largely unchanged. For instance, according to a report on 'New Perspectives on Global Health Spending for Universal Health Coverage' by WHO published in 2015, high-income countries with only 16% of the world's population, account for 80% of global health spending. Conversely, 76% of the world's population live in middle-income countries, but these account for less than 20% of global health spending. Low-income countries, with more than half a billion people, accounted for less than 1% of the world's health spending in 2015. Thus, low healthcare spending in low income countries limits such countries for research and development of new drugs for treatment of rare diseases.

Key features of the study:

This report provides in-depth analysis of the global progressive familial intrahepatic cholestasis type 2 treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global progressive familial intrahepatic cholestasis type 2 treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Teva Pharmaceutical Industries Ltd., AbbVie, Inc., Glenmark Pharmaceuticals Limited, Par Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc., Sanofi S.A., Novartis International AG, Akorn, Inc., Albireo Pharma, Inc. and Mirum Pharmaceuticals
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global progressive familial intrahepatic cholestasis type 2 treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for progressive familial intrahepatic cholestasis type 2 treatment market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug:
- Ursodeoxycholic acid
- Cholestyramine
- Rifampicin
- Late Stage Pipeline Drugs
- Others
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- Teva Pharmaceutical Industries Ltd.
- AbbVie, Inc.
- Glenmark Pharmaceuticals Limited
- Par Pharmaceuticals, Inc.
- Mylan N. V.
- Sanofi S.A.
- Novartis International AG
- Akorn, Inc.
- Albireo Pharma, Inc.
- Mirum Pharmaceuticals

Product Code: CMI4399

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Recent Trends & Key Developments
Regulatory Scenario
PEST Analysis
PORTER's Analysis
Mergers, Acquisitions and Collaborations

4. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Drug, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Ursodeoxycholic acid
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Cholestyramine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Rifampicin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Late Stage Pipeline Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
- Segment Trends
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (US$ Mn)
- Segment Trends

6. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Distribution Channel, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market, By Region, 2020 - 2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021-2032
- Segment Trends
North America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, Y-o-Y Growth By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country, 2020 -2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, Y-o-Y Growth, By Drug, 2020-2032, (US$ Mn)
- Market Size and Forecast, Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, By Country, Y-o-Y Growth, By Country/Region, 2020 -2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Teva Pharmaceutical Industries Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- AbbVie, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Glenmark Pharmaceuticals Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Par Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan Pharmaceuticals, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi S.A.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mylan N.V.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Novartis International AG
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Akorn, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Albireo Pharma, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Mirum Pharmaceuticals
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Jadeite Medicines Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Ipsen Pharma
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
  - Analyst's Views

9. Section

References
Research Methodology
About us and Sales Contact